Show simple item record

dc.contributor.authorRincón, Esther 
dc.contributor.authorCejalvo, Teresa 
dc.contributor.authorKanojia, Deepak
dc.contributor.authorAlfranca, Arantzazu 
dc.contributor.authorRodriguez-Milla, Miguel A 
dc.contributor.authorGil Hoyos, Raul Andrés
dc.contributor.authorHan, Yu
dc.contributor.authorZhang, Lingjiao
dc.contributor.authorAlemany, Ramón
dc.contributor.authorLesniak, Maciej S
dc.contributor.authorGarcia-Castro, Javier 
dc.date.accessioned2020-04-17T15:58:38Z
dc.date.available2020-04-17T15:58:38Z
dc.date.issued2017-07-11
dc.identifier.citationOncotarget. 2017 Jul 11;8(28):45415-45431.es_ES
dc.identifier.issn1949-2553es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9612
dc.description.abstractOncolytic virotherapy represents a promising alternative for cancer treatment; however, viral delivery to the tumor represents a major challenge. Mesenchymal stem cells (MSCs) chemotax to tumors, and can serve as a viral delivery tool. Previously, we demonstrated antitumor therapeutic efficacy for mesenchymal stem cells (MSCs) infected with the oncolytic human adenovirus ICOVIR5 (Celyvir) for treatment of neuroblastoma patients. Given the lack of suitable immunocompetent preclinical models, the mechanism underlying Celyvir antitumor activity remains unknown. In this study, we used the syngeneic murine CMT64 cell line as a human adenovirus-semi-permissive tumor model and demonstrate the homing capacity of mouse Celyvir (mCelyvir) to CMT64 tumors. We found that the combined treatment of mCelyvir and intratumoral injections (i.t.) of ICOVIR5 was more effective than treatment with i.t. ICOVIR5 alone. Interestingly, the superior therapeutic effect of the combined therapy was associated with a higher tumor infiltration of CD8+ and CD4+ T cells. Our findings suggest that the use of MSCs as carriers of oncolytic adenovirus can improve the clinical efficacy of anti-cancer virotherapy, not only by driving the adenovirus to tumors, but also through their potential to recruit T cells.es_ES
dc.description.sponsorshipThis work was supported by grants from the Fondo de Investigaciones Sanitarias (PI05/2217; PI08/0029; PI14CIII/00005), RTICC (RD12/0036/0015; RD12/0036/0027) and the Madrid Regional Government (S-BIO-0204-2006, MesenCAM; P2010/BMD-2420, CellCAM) in Spain to JG-C. ER and TC are supported by the “Sara Borrell” program of the Instituto de Salud Carlos III. The experiments were approved by the appropriate committees.es_ES
dc.language.isoenges_ES
dc.publisherImpact Journalses_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectcanceres_ES
dc.subjectcarrierses_ES
dc.subjectimmunotherapyes_ES
dc.subjectmesenchymal stem cellses_ES
dc.subjectoncolytic adenoviruseses_ES
dc.subject.meshAnimals es_ES
dc.subject.meshCell Line, Tumor es_ES
dc.subject.meshCell Movement es_ES
dc.subject.meshCell Survival es_ES
dc.subject.meshCytokines es_ES
dc.subject.meshDisease Models, Animales_ES
dc.subject.meshGene Expression es_ES
dc.subject.meshGenes, Reporter es_ES
dc.subject.meshGenetic Therapy es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunotherapy es_ES
dc.subject.meshInflammation Mediators es_ES
dc.subject.meshLymphocytes, Tumor-Infiltrating es_ES
dc.subject.meshMesenchymal Stem Cells es_ES
dc.subject.meshMice es_ES
dc.subject.meshTransduction, Genetices_ES
dc.subject.meshXenograft Model Antitumor Assays es_ES
dc.subject.meshAdenoviridae es_ES
dc.subject.meshGenetic Vectors es_ES
dc.subject.meshMesenchymal Stem Cell Transplantation es_ES
dc.subject.meshOncolytic Virotherapy es_ES
dc.subject.meshOncolytic Viruses es_ES
dc.titleMesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse modeles_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID28525366es_ES
dc.format.volume8es_ES
dc.format.number28es_ES
dc.format.page45415-45431es_ES
dc.identifier.doi10.18632/oncotarget.17557es_ES
dc.contributor.funderFondo de Investigaciones Sanitariases_ES
dc.contributor.funderComunidad de Madrides_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1949-2553es_ES
dc.relation.publisherversionhttps://doi.org/10.18632/oncotarget.17557es_ES
dc.identifier.journalOncotargetes_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI05/2217es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI08/0029es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI14CIII/00005es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0036/0015es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0036/0027es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/S-BIO-0204-2006es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/P2010/BMD-2420es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional